Literature DB >> 16054616

Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities.

Mahmood Aghaei1, Fatemeh Karami-Tehrani, Siamak Salami, Morteza Atri.   

Abstract

OBJECTIVE: The potential relationship between adenosine deaminase activity and cancer progression was examined by investigating the activity of total ADA and its isoenzymes in serum and simultaneously in the cancerous tissue of each patient with breast cancer.
METHODS: Total ADA and its isoenzymes were measured using the Giusti method. ADA2 activity was measured in the presence of a specific ADA1 inhibitor, EHNA.
RESULTS: Our results indicated that ADA2 and total ADA activities were higher in serum and malignant tissues than those of corresponding controls (P < 0.05). Tumor ADA2 and total ADA activities were significantly (P < 0.05) correlated with lymph node involvement, histological grade and tumor size, whereas their levels in serum were significantly (P < 0.05) correlated with menopausal status and patient age.
CONCLUSION: Although serum and tumor total ADA activity and its ADA2 isoenzyme were both found to be increased, distinct correlation patterns were observed with some of the prognostic factors. It can be speculated that increased ADA and isoenzyme activities in serum originated from sources other than the breast tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054616     DOI: 10.1016/j.clinbiochem.2005.05.015

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  23 in total

1.  De novo assembly of a haplotype-resolved human genome.

Authors:  Hongzhi Cao; Honglong Wu; Ruibang Luo; Shujia Huang; Yuhui Sun; Xin Tong; Yinlong Xie; Binghang Liu; Hailong Yang; Hancheng Zheng; Jian Li; Bo Li; Yu Wang; Fang Yang; Peng Sun; Siyang Liu; Peng Gao; Haodong Huang; Jing Sun; Dan Chen; Guangzhu He; Weihua Huang; Zheng Huang; Yue Li; Laurent C A M Tellier; Xiao Liu; Qiang Feng; Xun Xu; Xiuqing Zhang; Lars Bolund; Anders Krogh; Karsten Kristiansen; Radoje Drmanac; Snezana Drmanac; Rasmus Nielsen; Songgang Li; Jian Wang; Huanming Yang; Yingrui Li; Gane Ka-Shu Wong; Jun Wang
Journal:  Nat Biotechnol       Date:  2015-05-25       Impact factor: 54.908

Review 2.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

3.  Oxidative stress and its relationship with adenosine deaminase activity in various stages of breast cancer.

Authors:  Mridula Mahajan; Nitika Tiwari; Ritu Sharma; Sukhraj Kaur; Neetirajan Singh
Journal:  Indian J Clin Biochem       Date:  2012-08-17

4.  Posterior mediastinal tuberculous lymphadenitis with dysphagia as the main symptom: a case report and literature review.

Authors:  Liangkun Xiong; Xiaowen Mao; Changsheng Li; Zhisu Liu; Zhonglin Zhang
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

5.  Downregulation of metabolic activity increases cell survival under hypoxic conditions: potential applications for tissue engineering.

Authors:  Jaehyun Kim; Karl-Erik Andersson; John D Jackson; Sang Jin Lee; Anthony Atala; James J Yoo
Journal:  Tissue Eng Part A       Date:  2014-07-02       Impact factor: 3.845

6.  Myelomatous pleural effusion as an initial sign of multiple myeloma-a case report and review of literature.

Authors:  Li-Li Zhang; Yuan-Yuan Li; Cheng-Ping Hu; Hua-Ping Yang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

7.  Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors.

Authors:  Fatemeh Karami-Tehrani; Amin Rahimi Malek; Zahra Shahsavari; Morteza Atri
Journal:  Tumour Biol       Date:  2016-01-09

8.  Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer.

Authors:  Daniela Zanini; Roberta Schmatz; Luana Paula Pelinson; Victor Camera Pimentel; Pauline da Costa; Andréia Machado Cardoso; Caroline Curry Martins; Christina Chitolina Schetinger; Jucimara Baldissareli; Maria do Carmo Araújo; Liliane Oliveira; Juarez Chiesa; Vera Maria Morsch; Daniela Bitencourt Rosa Leal; Maria Rosa Chitolina Schetinger
Journal:  Mol Cell Biochem       Date:  2012-11-18       Impact factor: 3.396

9.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

10.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.